Psoriatic Arthritis Video Perspectives

Healio spoke with expert rheumatologists about recent advancements in psoriatic arthritis, how clinicians can approach patients with multidomain presentations of PsA, racial and ethnic disparities in disease activity and clinical outcomes, greatest areas of unmet need and more.

In this video interview, Joseph F. Merola, MD, MMSc, associate professor, vice chair of clinical trials and innovation and dermatology director of the Center for Skin and Related Musculoskeletal Diseases at Harvard Medical School; and from the divisions of rheumatology and pharmacoepidemiology and pharmacoeconomics at Brigham and Women's Hospital, discussed:

highlights in psoriatic arthritis presented at the AAD, ACR and EULAR conferences this year, including research on P19 inhibitors, secukinumab (Cosentyx, Novartis) for axial manifestations in PsA, an IL-17 A/F inhibitor and “compelling data” on upadacitinib (Rinvoq, AbbVie);
safety data on COVID-19 and the benefits and difficulties of telehealth;
the importance of guselkumab (Tremfya, Janssen), the first IL-23 inhibitor FDA-approved for psoriatic arthritis, from dermatologic and rheumatologic perspectives;
head-to-head drug trials in psoriatic arthritis and questions for future studies;
hard-to-treat patient subsets and treatment considerations for different subtypes; and
greatest areas of unmet need in psoriatic arthritis, such as getting patients to deep remission and maximizing quality of life, addressing malignancies over the course of disease, the risk of cardiovascular disease and the need for innovation for recalcitrant areas of the skin.